Subtopic Deep Dive
Recombinant Coagulation Factors
Research Guide
What is Recombinant Coagulation Factors?
Recombinant coagulation factors are genetically engineered proteins replicating factor VIII and IX used in hemophilia treatment to replace deficient clotting factors with reduced pathogen transmission risks compared to plasma-derived products.
This subtopic covers pharmacokinetics, immunogenicity, and efficacy of recombinant factor VIII and IX versus plasma-derived alternatives. Half-life extended formulations improve dosing intervals. Over 10 key papers from 1993-2017 document clinical trials and biochemical analyses.
Why It Matters
Recombinant factors minimize viral transmission risks inherent in plasma-derived products, enhancing patient safety in hemophilia A and B therapy (Sadler, 1998). Gene therapy trials using recombinant factor IX variants achieve sustained expression, enabling prophylaxis termination and reducing bleeding episodes (George et al., 2017). High-dose recombinant factor VIII immune tolerance regimens succeed in 70% of inhibitor cases, improving outcomes in severe hemophilia (Hay and DiMichele, 2011). These advances lower treatment burdens and hospitalization rates worldwide.
Key Research Challenges
Immunogenicity of Recombinant Factors
Recombinant factor VIII triggers inhibitors in 25-30% of severe hemophilia A patients, complicating therapy. Immune tolerance induction varies by dose regimen (Hay and DiMichele, 2011). Acquired hemophilia A autoantibodies further challenge treatment efficacy (Delgado et al., 2003).
Pharmacokinetics Variability
Half-life differences between factor VIII and IX products demand personalized dosing. Plasma levels of activated factor VII require precise quantitation for hemostasis monitoring (Morrissey et al., 1993). High-specific-activity variants aim to extend duration but face activity thresholds (George et al., 2017).
Thromboembolic Risks
Recombinant activated factor VIIa increases arterial thrombosis by 5% in hemorrhage trials despite hemostatic benefits (Mayer et al., 2005). Balancing bleeding control with cardiovascular safety remains critical in cirrhosis patients (Bosch et al., 2004).
Essential Papers
BIOCHEMISTRY AND GENETICS OF VON WILLEBRAND FACTOR
J. Evan Sadler · 1998 · Annual Review of Biochemistry · 1.4K citations
Von Willebrand factor (VWF) is a blood glycoprotein that is required for normal hemostasis, and deficiency of VWF, or von Willebrand disease (VWD), is the most common inherited bleeding disorder. V...
Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Stephan A. Mayer, Nikolai C. Brun, Kamilla Begtrup et al. · 2005 · New England Journal of Medicine · 1.2K citations
Treatment with rFVIIa within four hours after the onset of intracerebral hemorrhage limits the growth of the hematoma, reduces mortality, and improves functional outcomes at 90 days, despite a smal...
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
Lindsey A. George, Spencer K. Sullivan, Adam Giermasz et al. · 2017 · New England Journal of Medicine · 735 citations
We found sustained therapeutic expression of factor IX coagulant activity after gene transfer in 10 participants with hemophilia who received the same vector dose. Transgene-derived factor IX coagu...
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Savita Rangarajan, Liron Walsh, Will Lester et al. · 2017 · New England Journal of Medicine · 663 citations
The infusion of AAV5-hFVIII-SQ was associated with the sustained normalization of factor VIII activity level over a period of 1 year in six of seven participants who received a high dose, with stab...
Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation
James H. Morrissey, BG Macik, PF Neuenschwander et al. · 1993 · Blood · 502 citations
Abstract Although the majority of factor VII (FVII) circulates in the zymogen form, low levels of activated factor VII (FVIIa) have been postulated to exist in plasma and to serve a priming functio...
Acquired Haemophilia: Review and Meta‐Analysis Focused on Therapy and Prognostic Factors
Julio Delgado, Víctor Jiménez‐Yuste, F. Hernández‐Navarro et al. · 2003 · British Journal of Haematology · 462 citations
Acquired haemophilia (AH) is a rare disease that occurs at a rate of approximately 1 person per million each year. Anti-factor VIII is the most commonly recognized autoantibody directed against a c...
The principal results of the International Immune Tolerance Study: a randomized dose comparison
C. R. M. Hay, Donna DiMichele · 2011 · Blood · 432 citations
Abstract The International Immune Tolerance Study was a multicenter, prospective, randomized comparison of high-dose (HD; 200 IU/kg/d) and low-dose (LD; 50 IU/kg 3 times/week) factor VIII regimens ...
Reading Guide
Foundational Papers
Start with Sadler (1998) for VWF and coagulation basics (1355 citations), then Morrissey et al. (1993) for FVIIa quantitation methods (502 citations), followed by Hay and DiMichele (2011) immune tolerance results (432 citations) to build therapy context.
Recent Advances
Study George et al. (2017) FIX gene therapy (735 citations) and Rangarajan et al. (2017) FVIII transfer (663 citations) for sustained expression advances; Kruse-Jarres et al. (2017) updates acquired hemophilia guidance.
Core Methods
Tissue factor mutants quantitate activated factors (Morrissey et al., 1993); AAV vectors deliver high-specific-activity FIX (George et al., 2017); randomized dose comparisons test immune tolerance (Hay and DiMichele, 2011).
How PapersFlow Helps You Research Recombinant Coagulation Factors
Discover & Search
Research Agent uses searchPapers and citationGraph to map 432-citation Hay and DiMichele (2011) immune tolerance study connections to George et al. (2017) gene therapy. exaSearch uncovers half-life extended recombinant factor VIII trials; findSimilarPapers expands from Sadler (1998) VWF biochemistry to factor IX variants.
Analyze & Verify
Analysis Agent applies readPaperContent to extract pharmacokinetics data from Rangarajan et al. (2017), then runPythonAnalysis with pandas to compute half-life statistics across cohorts. verifyResponse (CoVe) with GRADE grading assesses evidence quality for inhibitor resolution rates; statistical verification confirms 70% success in Hay and DiMichele (2011).
Synthesize & Write
Synthesis Agent detects gaps in immunogenicity data between plasma-derived and recombinant factors, flagging contradictions in inhibitor rates. Writing Agent uses latexEditText, latexSyncCitations for Hay (2011), and latexCompile to generate formatted reviews; exportMermaid diagrams coagulation pathways from Sadler (1998).
Use Cases
"Compare half-life stats of recombinant FVIII vs FIX from clinical trials"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/matplotlib plots medians, IQR) → researcher gets CSV of half-lives with GRADE scores.
"Draft LaTeX review on rFVIIa thromboembolic risks in hemophilia"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Mayer 2005) + latexCompile → researcher gets PDF manuscript with diagrams.
"Find analysis code for factor VIII activity quantitation"
Research Agent → paperExtractUrls (Morrissey 1993) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets Python scripts for FVIIa assays.
Automated Workflows
Deep Research workflow synthesizes 50+ papers into structured report on recombinant vs plasma-derived efficacy, chaining citationGraph → readPaperContent → GRADE grading. DeepScan's 7-step analysis verifies immunogenicity claims from Hay (2011) with CoVe checkpoints and Python stats. Theorizer generates hypotheses on extended half-life formulations from George (2017) and Rangarajan (2017) data.
Frequently Asked Questions
What defines recombinant coagulation factors?
Genetically engineered factor VIII and IX proteins mimic natural clotting factors for hemophilia treatment, avoiding plasma-derived pathogen risks.
What methods assess recombinant factor efficacy?
Pharmacokinetic studies measure half-life and activity levels; immune tolerance trials compare high (200 IU/kg/d) vs low-dose regimens (Hay and DiMichele, 2011). Gene therapy vectors like AAV5-hFVIII-SQ normalize FVIII over 1 year (Rangarajan et al., 2017).
What are key papers on this topic?
Sadler (1998) covers VWF biochemistry (1355 citations); George et al. (2017) reports FIX gene therapy (735 citations); Hay and DiMichele (2011) details immune tolerance (432 citations).
What open problems exist?
Reducing inhibitor formation rates below 25%; minimizing rFVIIa thrombosis risks (Mayer et al., 2005); scaling gene therapy to broader hemophilia populations beyond high-dose responders.
Research Hemophilia Treatment and Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Recombinant Coagulation Factors with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Hemophilia Treatment and Research Research Guide